BELGRADE, MT / ACCESSWIRE / March 27, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and full year ended December 31,

Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative

Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of common stock at $7.20 per share. BELGRADE, Mont. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc.

Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse stock split. Approval of new directors to serve on its board. BELGRADE, Mont. , Feb.

Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus interest) of convertible notes into common stock Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse stock split of common stock Private placement of

Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported during the third quarter of 2016 Operating Expenses decreased 17% to $14.9 million , compared to $17.9

BELGRADE, Mont. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for

BELGRADE, Mont. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc.

BELGRADE, Mont. , Oct. 27, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the third quarter ended September 30, 2017 , after

BELGRADE, Mont. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced it will be showcasing its portfolio, featuring new technologies, at the 2017 annual North American